Yanagimachi, Tsuyoshi
Fujita, Yukihiro
Takeda, Yasutaka
Honjo, Jun
Atageldiyeva, Kuralay K.
Takiyama, Yumi
Abiko, Atsuko
Makino, Yuichi
Kieffer, Timothy J.
Haneda, Masakazu
Funding for this research was provided by:
Japan Society for the Promotion of Science (23591291)
Insulin Research Foundation
Japan Diabetes Foundation
Article History
Received: 1 September 2015
Accepted: 27 November 2015
First Online: 22 December 2015
Funding
: This research was supported in part by a research grant from Merck Investigator Initiated Studies Program. YF is supported by grants from the Japan Society for the Promotion of Science (Grant-in-Aid for Scientific Research [C] number 23591291), Japan Diabetes Foundation (Incretin Research) and Insulin Research Foundation (Novo Nordisk Pharma, Japan). YF also received scholarships from Eli Lilly, Pfizer and MSD.
: The authors declare that there is no duality of interest associated with this manuscript.
: TY, YF, Y Takeda, JH, KKA, Y Takiyama, AA, YM, TJK and MH contributed to the study concept and design. TJK produced the HEK293 cell lines co-transfected with human forms of GIPR or glucagon receptor, and a cyclic AMP-inducible luciferase expression construct. TY, YF, Y Takeda and KKA acquired the data. TY, YF, Y Takeda, JH, KKA, Y Takiyama, AA, YM, and MH analysed and interpreted the data. TY and YF drafted the manuscript. TY, YF, Y Takeda, KKA, JH, Y Takiyama, AA, YM, TJK and MH reviewed the manuscript for important intellectual content. All authors have approved the final version of this manuscript. YF and MH are the guarantors of this work.
Free to read: This content has been made available to all.